April 01, 2026 FDA Broadens CFTR Therapy Eligibility The FDA expanded use of CFTR modulators to include more CF gene variants, increasing treatment eligibility across a wider US patient population. Conexiant
March 31, 2026 Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy Phoenix Children's Medical Connection
March 31, 2026 Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy Phoenix Children's Medical Connection
5 FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa Conexiant
January 01, 2026 Prevent Blindness Honors Jim McGrann With 2026 Person of Vision Award Eyecare Business